Related Experiment Video
Updated: Jan 1, 2026

CIRCLE-Seq for Interrogation of Off-Target Gene Editing
Published on: November 1, 2024
How Should Gene Editing Be Managed by Risk Managers?
1A certified professional health care risk manager and a former federal executive with experience in multiple disciplines, including enterprise risk management, organizational ethics, high reliability, and patient safety.
Abstract:
Gene editing, because it is a new technology, presents challenges to health care organizations' risk managers. At this time, little claims data exists upon which to make informed decisions about loss control and to draw upon when developing risk mitigation strategies. This article explores gene editing through the eyes of risk managers and underwriters and concludes that traditional risk management tools must be used to reduce risk until more is known about the frequency and severity of claims.
Related Concept Videos
What is Genetic Engineering?
CRISPR
CRISPR/Cas9 Genome Editing
In-vitro Mutagenesis
CRISPR and crRNAs
The CRISPR-Cas system stores a copy of foreign DNA in the host genome and uses it to identify the foreign DNA upon reinfection. CRISPR-Cas has three different...
Gene Therapy

